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Abstract
 
Duchenne muscular dystrophy (DMD) is an X-linked, le-
thal disease caused by mutations of the dystrophin gene. No
effective therapy is available, but dystrophin gene transfer
to skeletal muscle has been proposed as a treatment for
DMD. We have developed a strategy for efficient in vivo
gene transfer of dystrophin cDNA into regenerating skeletal
muscle. Retroviral producer cells, which release a vector
carrying the therapeutically active dystrophin minigene,
were mitotically inactivated and transplanted in adult
nude/
 
mdx
 
 mice. Transplantation of 3
 
 
 
3
 
 10
 
6
 
 producer cells
in a single site of the tibialis anterior muscle resulted in the
transduction of between 5.5 and 18% total muscle fibers.
The same procedure proved also feasible in immunocompe-
tent 
 
mdx
 
 mice under short-term pharmacological immuno-
suppression. Minidystrophin expression was stable for up to
6 mo and led to
 
 
 
a
 
-sarcoglycan reexpression. Muscle stem
cells could be transduced in vivo using this procedure.
Transduced dystrophic skeletal muscle showed evidence of
active remodeling reminiscent of the genetic normalization
process which takes place in female DMD carriers. Overall,
these results demonstrate that retroviral-mediated dystro-
phin gene transfer via transplantation of producer cells is a
valid approach towards the long-term goal of gene therapy
of DMD. (
 
J. Clin. Invest.
 
 1997. 100:620–628
 
.
 
)
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Introduction
 
Duchenne muscular dystrophy (DMD)
 
1
 
 is an X-linked reces-
sive disease affecting 1 out of every 3,500 liveborn boys. It is
caused by mutations in the dystrophin gene, resulting in the
absence of dystrophin and related proteins in skeletal muscle
and other tissues (1, 2). In the early phase of the disease, skele-
tal muscle of DMD patients is characterized by an ongoing
process of degeneration and regeneration which is later fol-
lowed by exhaustion of the regenerative capacity, fibrosis,
phagocytic infiltration, and eventual disruption of the muscle
tissue architecture (2). The pathological process involving
skeletal muscle manifests clinically with progressive muscle
weakness and atrophy, confinement to a wheelchair before the
age of 12 and eventual death due to respiratory insufficiency
(2). No effective therapy is available at present and dystrophin
gene transfer has been proposed as a possible approach to
treat DMD.
The process of skeletal muscle degeneration and regener-
ation observed in young DMD patients and in the analogous
dystrophic 
 
mdx
 
 mice and 
 
xcmd 
 
dogs (3, 4) is sustained by the
muscle stem cell (or satellite cell) population. Muscle satellite
cells are mononucleated cells located along the myofibers be-
tween the sarcolemma and the basement membrane. They
are normally quiescent but can, under appropriate stimuli,
proliferate and fuse to form new fibers along the structural
framework provided by the basement membrane of damaged
fibers (5, 6). We have shown previously that the transplanta-
tion of retroviral producer cells in adult nude/
 
mdx
 
 mice leads
to the efficient in vivo infection of activated satellite cells and
the appearance of large numbers of transduced myofibers
(7). Furthermore, at least a proportion of the transduced sat-
ellite cells survived as stem cells and participated in the pro-
cess of muscle regeneration in the long term (7). Retroviral
producer cell clones releasing a vector which contains the
therapeutically active 6.3-kb dystrophin minigene (8) have
now been constructed and transplanted into regenerating
skeletal muscle of adult nude/
 
mdx
 
 and 
 
mdx
 
 mice under short-
term pharmacological immunosuppression. We have attempted
not only to evaluate the efficiency of retroviral-mediated dys-
trophin gene transfer in skeletal muscle, but also several
other important issues related to the pathophysiology of dys-
trophic muscle which are relevant to future applications of
gene therapy.
A variety of studies have shown that the full-length and the
Becker-type 6.3-kb dystrophin cDNAs are able to prevent the
onset of dystrophy when expressed in the 
 
mdx 
 
mouse muscle.
Such studies were based on dystrophin expression in trans-
genic 
 
mdx
 
 mice or on adenoviral-mediated dystrophin gene
transfer in newborn 
 
mdx
 
 mice (9–14). However, what is effec-
tive in preventing muscular dystrophy may not necessarily be
effective in reversing existing pathology and disorganization of
the extracellular matrix or changes in the normal muscle archi-
tecture may have irreversible pathological effects. Few studies
have addressed the problem of the therapeutic efficacy of the
dystrophin cDNAs when administered to young or adult 
 
mdx
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1. 
 
Abbreviations used in this paper:
 
 DAG, dystrophin associated glyco-
proteins; DMD, Duchenne muscular dystrophy; dys, minidystrophin
(229 kD); IRES, internal ribosome entry site; N-CAM, neural cell adhe-
sion molecule; 
 
Neo
 
, neomycin phosphotransferase; TA, tibialis anterior.
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mice (15, 16). Such an experimental setting is closer to the clin-
ical scenario since the pathology of skeletal muscle observed in
very young DMD patients is similar to the one observed in
adult 
 
mdx
 
 mice (2, 3).
A mosaic population of dystrophin competent and incom-
petent satellite cells is present in skeletal muscle of female
DMD carriers due to the random inactivation of one of the
two X-chromosomes in early embryonic life (17). Since mature
muscle fibers are syncytia derived from the fusion of embry-
onic myoblasts, in young DMD carriers there are myofiber
segments which do not express dystrophin and are therefore
more likely to degenerate (18). However, after repeated rounds
of degeneration and regeneration, the dystrophin competent
satellite cells are eventually recruited and newly formed fiber
segments stabilized. This is one of the mechanisms which leads
to the “normalization” of skeletal muscle of DMD carriers, that
is, to a progressive increase in the total number of dystrophin-
positive myofibers as carriers age (17). Therefore, we have also
attempted to evaluate whether a similar process is active in
dystrophic mouse skeletal muscle after in vivo retroviral-medi-
ated transduction of the dystrophin minigene.
 
Methods
 
Construction of the retroviral vector pDyBIN.
 
To construct the vector
pDyBIN [dystrophin Becker-type, IRES (internal ribosome entry
site), 
 
Neo
 
 (neomycin phosphotransferase)], the vector pLNEPN
(generous gift of Dr. A.D. Miller; reference 19) was digested with
EcoRI and BstXI to release the insert containing purine nucleoside
phosphorylase and 
 
Neo
 
 genes and leave the backbone free for subse-
quent cloning. A polylinker was inserted in the EcoRI/BstXI site.
The encephalomyocarditis virus IRES element fused to the 
 
Neo
 
 gene
(kind gift of Dr. B. McStay; reference 20) was inserted in the SnaBI/
PacI site of the polylinker by directional cloning. The resulting vector
pLIN was digested with NotI and SalI, and the Becker-type 6.3-kb
dystrophin cDNA obtained from pRSVDyB (21) was inserted by di-
rectional cloning to give the 9.8-kb pDyBIN provirus. In pDyBIN, the
dystrophin minigene and the 
 
Neo
 
 gene are separated by an IRES ele-
ment and are both transcribed from the viral long terminal repeats
(LTRs).
 
PCR.
 
The reaction was performed in 50 
 
m
 
l final volume contain-
ing 500 ng genomic DNA, 1
 
3
 
 PCR buffer (Stratagene, Cambridge,
United Kingdom), 8 mM MgCl
 
2
 
, 0.96 mM dNTPs, 8 U 
 
Taq
 
 poly-
merase (Stratagene), and 8 U 
 
Taq
 
 extender (Stratagene). Cycling pa-
rameters were: 94
 
8
 
C, 3 min as a single denaturing cycle; 94
 
8
 
C, 1 min;
55
 
8
 
C, 50 s; 72
 
8
 
C, 7 min over 30 cycles. Primer sequences were as fol-
lows: forward 
 
c
 
: 5
 
9
 
-CCTTCTGCTCTGCAGAATGGC-3
 
9
 
, which is
complementary to a region of the packaging signal of DyBIN vector
and reverse Neo: 5
 
9
 
-CCCGCTTCAGTGACAACGTCG-3
 
9
 
 which is
complementary to the 
 
Neo
 
 gene in the DyBIN vector (19). The PCR
product band has an expected length of 7.5 kb, corresponding to al-
most the entire DyBIN provirus with the exclusion of the LTRs.
 
Growth and maintenance of cells.
 
Mouse cell lines were grown in
DME (Sigma Chemical Co., Dorset, United Kingdom) supplemented
with 10% FCS (Sigma Chemical Co.) and 2 mM 
 
L
 
-glutamine at 37
 
8
 
C in
an atmosphere containing 8% CO
 
2
 
. Primary mouse muscle cultures
were grown on laminin-coated dishes in DME supplemented with 20%
FCS. Human muscle cultures were grown on merosin-coated dishes
in Ham-F10 media (Sigma Chemical Co.) supplemented with 2 mM
 
L
 
-glutamine, 20% FCS, 0.1 mg/ml insulin, 1 
 
m
 
M dexamethasone, 0.1
 
m
 
g/ml epidermal growth factor, and 0.1 
 
m
 
g/ml fibroblast growth fac-
tor (all purchased from Sigma Chemical Co.) at 37
 
8
 
C in an atmo-
sphere containing 5% CO
 
2
 
.
 
Construction of amphotropic and ecotropic retroviral producer
cell clones for dystrophin gene transfer.
 
The amphotropic packaging
cells GP
 
1
 
Am12 (22) were seeded in 60-mm dishes (1.5 
 
3
 
 10
 
4
 
 cells/cm
 
2
 
)
and transfected 24 h later with pDyBIN plasmid using lipofectamine-
mediated DNA complexes as previously described (23). After 72 h
cells were trypsinized and dispersed at various densities into 24-well
tissue culture dishes in the presence of 500 
 
m
 
g/ml G418 to provide di-
lution cloning conditions. 15 G418-resistant clones were isolated and
expanded. Genomic DNA was extracted from these clones and ana-
lyzed by PCR with 
 
c
 
/Neo primer set. Of 15 clones examined, 9 were
found to carry the unrearranged DyBIN vector and were then
checked for minidystrophin expression by Western blot. The four
dystrophin-positive clones were expanded and viral-containing super-
natants were collected and used to infect NIH 3T3 fibroblasts. In-
fected fibroblasts were selected in 500 
 
m
 
g/ml G418 for 12 d and viral
titers counted. To test the stability of the viral vector, individual poly-
clonal populations of NIH 3T3 fibroblast infected with supernatants
from the DyBIN clones were selected in G418, expanded, and sub-
jected to Western blot and PCR analysis. Polyclonal populations of
NIH 3T3 cells infected with virus produced from DyBIN clones 2 and
7 were expressing the minidystrophin and were carrying the intact
DyBIN provirus. No helper virus was found in the DyBIN clones 2
and 7 as checked by mobilization assay (2 wk; reference 24). DyBIN
clone 7 was found to have the highest titer (5 
 
3
 
 10
 
4
 
 cfu/ml). To pre-
pare a high titer ecotropic producer cell clone, AmpliGPE packaging
cells (25) were seeded in 3-cm
 
2
 
 wells (6 
 
3
 
 10
 
4
 
 cells/cm
 
2
 
) and infected
with 1 ml of retroviral-containing supernatants from DyBIN 7 am-
photropic producer cell clone. The procedure was repeated six times
every 3 or 4 d and then the infected AmpliGPE cultures were cloned
by limiting dilution. 23 ecotropic clones were isolated and analyzed
by PCR and Western blot as previously described for the amphotro-
pic clones. Ecotropic clones which were carrying the intact DyBIN
vector and were expressing the 229-kD minidystrophin (clone names:
AmpliDyBIN 1, 10, 20, and 21, respectively) were then screened for
titer of released virus. Clone AmpliDyBIN 1 had a titer of 2 
 
3
 
 10
 
5
 
cfu/ml and was found to be helper virus–free by mobilization assay.
 
Preparation of retroviral producer cells for transplantation.
 
About 10
 
6
 
 AmpliDyBIN 1 producer cells were seeded in 100-mm tis-
sue culture dishes in the presence of 1–1.5 
 
m
 
g/ml mitomycin C (Sigma
Chemical Co.) for 16 h. Cells were then washed twice in PBS 
 
1
 
0.02% EDTA (very briefly to avoid detachment), trypsinized, resus-
pended in a small volume (generally 10–50 
 
m
 
l) of Hepes-buffered
DME, and held in ice until used.
 
Dissociation of mouse and human muscle tissue and infection of
primary myoblasts.
 
Mouse muscle tissue was dissociated as previ-
ously described (26). All human samples were collected for diagnostic
purposes after informed consent (courtesy of Department of Histo-
pathology, UMDS Guy’s Hospital, London, United Kingdom). Mus-
cle samples were washed several times in PBS, transferred in Ham-
F10 media, and then minced into 
 
,
 
 5-mm diameter pieces using fine
scissors. Muscle pieces were seeded into plastic tissue culture dishes
to allow satellite cell spread. After 7–10 d, cultures were trypsinized,
filtered through a 50 
 
m
 
m sterile nylon filter, and plated onto merosin-
coated dishes (5 
 
m
 
g/ml; Chemicon International Co., Temecula, CA).
Viral-containing supernatants were added in the presence of 8 
 
m
 
g/ml
polybrene when primary myoblasts reached 50–60% confluency. Hu-
man and mouse myoblasts were induced to differentiate to myotubes
by changing the medium to DME supplemented with 5% heat-inacti-
vated horse serum. Cultures were analyzed for immunocytochemistry
and Western blot 10 d later.
 
Immunocytochemistry and immunohistochemistry.
 
Monoclonal
antibody (mAb) Dy8/6C5 against the carboxy terminus of dystrophin
(residues 3668–3685) (27, 28) and mAb Ad1/20A6 against 
 
a
 
-sarcogly-
can were a gift of Dr. L. Anderson (Newcastle General Hospital,
United Kingdom). mAb MANDYS1 biotinylated against the rod do-
main of dystrophin was a gift of Drs. N.-T. Man and G. Morris (North
East Wales Institute, United Kingdom) (29, 30). P6 is a rabbit poly-
clonal antibody against the carboxy-terminal repeat region of the rod
domain of dystrophin (31). mAb D33 against desmin was purchased
from Dako Ltd. (Bucks, United Kingdom). Rat mAb against the neu-
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ral cell adhesion molecule (N-CAM) H-28 was a gift of Dr. S. Moore
(Guy’s Hospital, London, United Kingdom) (32). Secondary antibod-
ies were: biotinylated anti–mouse Ig and IgG (from sheep), biotinyl-
ated anti–rabbit IgG (from donkey) (Amersham International, Buck-
inghamshire, United Kingdom) and fluorescein-conjugated anti–rat
IgG from goat (Sigma Chemical Co.). Streptavidin Texas red was
purchased from Amersham. Immunocytochemical staining for dys-
trophin detection was performed as previously described (33). For
immunohistochemistry, tissues were snap frozen in liquid N
 
2
 
-cooled
isopentane. Cryostat sections were blocked in PBS containing 10%
(vol:vol) FCS (in the case of P6 antibody) or 10% FCS 
 
1
 
 10% normal
rabbit serum (in the case of mouse mAb) for 30 min at room temper-
ature. Primary antibody was then added for 30 min. After three wash-
ing steps of 10 min each, biotinylated secondary antibody was added
for 30 min and samples were washed as before. For immunofluo-
rescence analysis, samples were incubated 30 minutes with streptavi-
din Texas red, washed three times in PBS, and mounted. For light
microscopy analysis, samples were incubated with alkaline phospha-
tase or horseradish peroxidase–conjugated ABC solution (Dako),
washed three times, and finally incubated in Sigma 
 
FAST
 
 BCIP/NTB
(5-bromo-4-chloro-indolyl phosphate and nitro blue tetrazolium) or
Sigma 
 
FAST
 
 DAB tablets (3,3
 
9
 
-diaminobenzidine tetrahydrochlo-
ride) solutions prepared according to the manufacturer’s instructions
at 4
 
8
 
C for 1–3 min. Sections were then washed in water, dehydrated in
methanol, and mounted.
 
SDS-PAGE and Western blot.
 
Cell cultures (100-mm dishes) were
rinsed twice in PBS and then collected in 150–200 
 
m
 
l sample buffer
(75 mM Tris, pH 6.8, 10% SDS, 0.1% bromophenol blue, 20% glyc-
erol, 100 mM DTT, 20 
 
m
 
g/ml PMSF, 0.06 mg/ml antipain, 0.01 mg/ml
aprotinin, 0.5 
 
m
 
g/ml leupeptin hemisulphate, 0.2 mg/ml EDTA, all pur-
chased from Sigma Chemical Co.) passed through a 25 gauge needle
to fragment the DNA and heated at 100
 
8
 
C for 5 min. Samples were
loaded on a 7.5% polyacrylamide gel and Western blotting was then
performed as previously described (13). For desmin detection, after
the transfer and blocking steps, the membrane was incubated for 2 h
at room temperature with vigorous shaking with a mixture of anti-
desmin mAb D33 (diluted 1:50) and antidystrophin mAb Dy8/6C5
(diluted 1:20).
 
Animals.
 
A colony of C57BL/10
 
mdx
 
 (
 
mdx
 
) mice and Nude/
 
mdx
 
mice was kindly provided by Prof. T. Partridge (Hammersmith Hos-
pital, London, United Kingdom). C57BL/10 mice were purchased
from Harlan Olac (Bicester Oxon, United Kingdom).
 
Anesthesia.
 
Mice were anesthetized by intraperitoneal injection
of a mixture of the anesthetics Hypnorm (fentanyl-fluonasone; Jan-
sen Pharmaceutica, High Wycombe, Buckinghamshire, United King-
dom) and Hypnovel (midazolam; Roche Laboratories, Nutley, NJ) in
sterile distilled water in the ratio 1:1:2 according to Flecknell (34). 5–7
ml of freshly prepared mixture was injected intraperitoneally per ki-
logram of body weight using a gauge 27 hypodermic needle.
 
Muscle degeneration and infection.
 
Tibialis anterior (TA) mus-
cles were degenerated by injection of 30–50 
 
m
 
l 1.2% BaCl
 
2
 
 in normal
saline (35). Approximately 30–50 
 
m
 
l of producer cell suspension was
injected in a single shot 4–6 h after muscle degeneration.
 
Immunosuppression of animals.
 
The immunosuppressive drug
FK506 (Fujisawa Pharmaceuticals, Osaka, Japan) was freshly diluted
at a final concentration of 1 mg/ml, and injected intraperitoneally (2.5
mg/kg per d) for 6 d, starting 1 d before cell implantation.
 
Statistical analysis.
 
Statistical significance was assessed by Stu-
dent’s 
 
t
 
 test. 
 
P
 
 
 
,
 
 0.05 was taken as significant. Data are expressed as
means
 
6
 
SD.
 
Results
 
Infection of mouse and human myoblasts in vitro.
 
The ampho-
tropic DyBIN 7 and the ecotropic AmpliDyBIN 1 producer
Figure 1. Immunocytochemical staining of 
human and mouse myotubes with Dy8/6C5 
antidystrophin antibody. Primary cultures 
from mdx and C57BL/10 mouse or DMD 
patient were grown in laminin or merosin-
coated dishes. Primary cultures from 
C57BL/10 mouse (a) and mdx mouse (b) 
were induced to differentiate to myotubes 
by changing the medium to 5% horse se-
rum. Fresh amphotropic virus (500 ml) was 
used to infect DMD myoblasts (c) and 
fresh ecotropic virus (300 ml) was used to 
infect mdx mouse myoblasts (d) which 
were then induced to differentiate as above 
(3200).
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cell clones were tested for the ability to infect in vitro human
and mouse myoblasts, respectively, and to express the mini-
dystrophin. After infection, mouse or human myoblasts were
allowed to differentiate into myotubes and were immunocy-
tochemically stained for dystrophin (Fig. 1). No staining was
observed in uninfected mdx and DMD cultures. In infected
cultures before fusion only very rarely was specific dystrophin
staining observed in mononucleated cells. About a week after
myoblasts differentiated into myotubes, dystrophin was de-
tected at the sub-sarcolemmal region. In a few myotubes,
patches of cytoplasmic staining were also observed. Confocal
microscopy confirmed that dystrophin was mainly localized at
the myotube surface membrane. Infected human DMD myo-
blasts were also selected in G418 for 1 wk and analyzed by
Western blot either before or after fusion into myotubes. The
minidystrophin was expressed in infected human myoblasts
and myotubes, consistent with the fact that the viral LTR is not
developmentally regulated (not shown). In transduced DMD
myotubes minidystrophin appeared to be expressed at levels
comparable to endogenous dystrophin (Fig. 2).
Transplantation of retroviral producer cells for dystrophin
gene transfer. AmpliDyBIN 1 producer cells were mitotically
inactivated by treatment with mitomycin C, the left TA mus-
cles of 18 6-wk-old nude/mdx mice were artificially degener-
ated and cells were injected 4–6 h after muscle degeneration.
Treated animals were divided in two groups, depending on the
number of transplanted cells: 12 animals received 2.5 3 105
producer cells and 6 animals received 3 3 106 cells. Nude/mdx
mice which received the lower dose of cells were killed at 6 wk
(4 mice), 12 wk (4 mice), and 24 wk (4 mice) after producer
cell transplantation. Nude/mdx mice which received 3 3 106
cells were all killed 6 wk after cell transplantation. At all time
points hematoxylin and eosin staining of treated TA muscles
showed no morphological differences compared to sham in-
jected mdx mouse TA muscles. As shown in Fig. 3 and Table I,
large numbers of minidystrophin expressing (dys1) fibers were
counted in all treated muscles (5.5–18% of total muscle fibers).
Immunostaining of serial sections with mAb MANDYS1
showed only very few (20610) dys1 fibers, consistent with the
pattern observed with P6 antibody in control mdx mice (not
shown). This indicated that the vast majority of dys1 fibers de-
tected with P6 antibody were expressing the Becker-type hu-
man dystrophin cDNA, for the region recognized by mAb
MANDYS1 is deleted in the 229-kD Becker minidystrophin
(8, 29). With regard to the time course experiment, no signifi-
cant difference was found in the number of dys1 fibers at 6, 12,
and 24 wk after producer cell transplantation (Student’s t test,
P . 0.5). However, a statistically significant twofold increase
was found between the group of mice injected with 3 3 106
producer cells and the group injected with 2.5 3 105 producer
cells (Student’s t test, P , 0.02).
Producer cells can be transplanted in immunocompetent
mice under short-term immunosuppression. To evaluate the
feasibility of this approach in immunocompetent mice, a short-
term immunosuppression regimen was designed to avoid the
rapid rejection of the implanted cells which was observed in a
previous study (7). The immunosuppressive drug FK506 (tac-
rolimus) was chosen, for it has been successfully used to con-
trol rejection in myoblast transplantation experiments (36).
The left TA muscle of 14 5-wk-old immunocompetent mdx
mice was degenerated as before and injected with 106 Am-
pliDyBIN 1 retroviral producer cells 4–6 h later. Seven mice re-
ceived mitomycin C–treated cells and the other seven received
untreated, mitotically active cells. All mice were killed after 3 wk.
Figure 2. Dystrophin 
expression in human 
myotube cultures. 
DMD cultures (lane 1), 
DMD cultures infected 
with amphotropic virus 
(lane 2), or normal hu-
man cultures (lane 3) 
were collected in sam-
ple buffer, loaded on a 
7.5% polyacrylamide 
gel and then analyzed 
by Western blot. Pri-
mary antibodies were 
antidystrophin Dy8/
6C5 and antidesmin 
D33. Right margin indi-
cates Mr 3 1023. D, dys-
trophin (full length); 
Dy, dystrophin (mini-
gene); De, desmin.
Table I. Number of dys1 Fibers After Transplantation of AmpliDyBIN 1 Retroviral Producer Cells
Mouse strain
Weeks after
injection No. of dys1 fibers Mean6SD Percent range
Percentage of clustered dys1
fibers (mean6SD)
Nude/mdx (2.5 3 105 cells) 6 170/136/100/106 128628 6–9.5 2.560.5
Nude/mdx (2.5 3 105 cells) 12 305/92/146/100 160686 5.5–17 16.3611
Nude/mdx (2.5 3 105 cells) 24 185/78/70 111652 4–10.2 12.564
Nude/mdx (3 3 106 cells) 6 325/270/230/185/160/132 217666 7.3–18 ND
mdx (106 cells) 3 164/144/107/96/90/81/83 109630 4.6–9.1 ND
AmpliDyBIN 1 producer cells were treated with mitomycin C and injected into TA muscles which were degenerated 4–6 h before using BaCl2. The
number of cells transplanted is indicated in brackets. Transduced dys1 fibers were counted on sections immunostained with antidystrophin P6 poly-
clonal antibody. Data points from different animals are separated by slashes. A TA muscle of an mdx mouse is composed of 18006250 myofibers.
ND, not done.
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The efficiency of dystrophin gene transfer in temporarily
immune-suppressed mdx mice which received mitomycin
C–treated cells was as good as that obtained in nude/mdx mice
(Fig. 3 D and Table I). Muscle morphology showed no abnor-
mality compared to mdx controls. However, substantial in-
flammatory infiltration and fibrosis were apparent in the TA
muscles which received implants of nonmitomycin C–treated
cells (Fig. 3 E) and the number of dys1 fibers was not counted.
This suggested that an immunoreaction occurred after FK506
withdrawal, probably as a consequence of producer cell prolif-
eration during the period of immunosuppression.
Reexpression of a-sarcoglycan in transduced fibers. Dystro-
phin is associated at the sarcolemma with a complex of pro-
teins and glycoproteins (namely a- and b-dystroglycans, a-, b-,
and g-sarcoglycans; reference 37). The correct assembly of
dystrophin with the associated protein complex (DAG) ap-
pears to be essential to prevent muscular dystrophy (38, 39).
Serial sections of the TA muscles injected with AmpliDyBIN 1
producer cells 6 and 12 wk earlier were immunostained for
a-sarcoglycan detection. As shown in Fig. 4, z 65% trans-
duced dys1 fibers were also positive for a-sarcoglycan, suggest-
ing that in many cases the DAG complex was at least in part
restored at the sarcolemma. Immunostaining of serial sections
with mAb MANDYS1 showed that the fibers staining posi-
tively for a-sarcoglycan were not revertants. More than 75%
a-sarcoglycan positive fibers were still centrally nucleated 12
wk after gene transfer.
Retrovirally transduced skeletal muscle undergoes active re-
modeling. To investigate whether satellite cells could be in-
fected in vivo with the retroviral vector carrying the dystrophin
minigene, the TA muscles of four 9-wk-old nude/mdx mice
were degenerated with BaCl2 and injected 4 h later with 5 3
Figure 3. Immunohistochemistry for dys-
trophin detection in mdx mice muscle sec-
tions. TA muscles were degenerated with 
BaCl2 and 4–6 h later retroviral producer 
cells were transplanted. Nude/mdx mice 
received 2.5 3 105 (A and C, 3200; F, 
3400) or 3 3 106 (B, 3200) mitomycin
C–treated AmpliDyBIN 1 producer cells 
and killed after 6 wk (A, B), 12 wk (C) or 
24 wk (F). Temporarily immunosup-
pressed mdx mice received 106 mitomycin 
C–treated (D, 3200) or untreated
(E, 3200) AmpliDyBIN 1 producer cells 
and were killed after 3 wk.
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105 mitomycin C–treated producer cells. Mice were killed 3 mo
later. Treated TA muscles were dissociated to release mono-
nucleated satellite cells. Primary cultures were selected in me-
dia containing 200 mg/ml G418 for 12 d. At the end of the se-
lection procedure, cells obtained from untreated muscles all
died whereas G418-resistant populations were clearly obtained
from the transplanted TA muscles. To exclude the presence of
replication competent virus or active producer cells in the tis-
sue culture samples, culture media were collected from conflu-
ent (G418-resistant) primary cells and used to infect NIH 3T3
Figure 4. Immunohisto-
chemistry for dystrophin 
and a-sarcoglycan detec-
tion. Muscle sections of 
C57BL/10 mouse (A, 
3200) and mdx mouse 
(B, 3200) were immuno-
stained with Ad1/20A6 
anti a-sarcoglycan anti-
body. Sections 250 mm 
apart of the same nude/
mdx mouse muscle trans-
planted 12 wk before with 
AmpliDyBIN 1 producer 
cells were immunostained 
for detection of dystro-
phin (C, 3200; E, 3400) 
and a-sarcoglycan (D, 
3200; F, 3400).
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fibroblasts. No G418-resistant NIH 3T3 cell population was
detected after 2 wk of culture. The primary cultures were also
analyzed by Western blotting. As shown in Fig. 5, a dys band
was clearly detectable. Immunostains of tissue sections dem-
onstrated the presence of dys1 mononucleated cells positioned
at the periphery of muscle fibers, some of which were also pos-
itive for N-CAM, which is a marker of myogenic cells (40, 41)
(Fig. 5). Thus, these cells were tentatively identified as satellite
cells.
Taken together, these data suggested that satellite cells had
been infected in vivo by the DyBIN virus. Moreover, TA mus-
cles of nude/mdx mice transplanted with producer cells 3 and
6 mo earlier showed the presence of large clusters of dys1 fi-
bers (Fig. 3) which were never detected at earlier time points,
not even in the mice transplanted with 3 3 106 producer cells.
To quantitate this observation, the percentage of dys1 fibers
which were completely surrounded by other dys1 fibers at
each time point was counted. On average, one myofiber is sur-
rounded by four to six fibers. As shown in Table I, the percent-
age of clustered dys1 fibers increased fivefold 12 and 24 wk after
dystrophin gene transfer compared to 6 wk and the difference
was statistically significant (Student’s t test: 6 wk versus 12 wk,
P , 0.05; 6 wk versus 24 wk; P , 0.005). To evaluate whether
the clustering effect was due to de novo fusion of transduced
satellite cells, sections of treated TA muscles of each time point
(6, 12, and 24 wk after transplantation) were double immuno-
labeled with antibodies against dystrophin and N-CAM, which
is specifically expressed in regenerating myofibers (32, 40, 41).
Groups of dys1 and N-CAM2 fibers were frequently found ad-
jacent to dys1 and N-CAM1 fibers in TA muscles analyzed
6 wk after transplantation but not in muscles analyzed at later
time points (Fig. 6). As shown in Fig. 7, the percentage of
N-CAM1 fibers in the dys1 fiber population decreased three-
fold in treated TA muscles of mice killed 12 and 24 wk after
cell transplantation compared to the mice killed after 6 wk and
the difference was statistically significant (Student’s t test: 6 wk
versus 12 wk, P , 0.0001; 6 wk versus 24 wk, P , 0.0001). The
percentage of N-CAM1 and dys2 fibers did not decrease in
older animals (Fig. 7).
Discussion
The procedure based on the transplantation of retroviral pro-
ducer cells into regenerating skeletal muscle proved to be a
successful approach for dystrophin gene transfer in mdx mouse
muscle. The quantity of producer cells transplanted into regen-
erating muscle appeared to be an important factor, since a
twofold difference in the number of dys1 fibers was observed
between the groups of mice injected with 2.5 3 105 and 3 3 106
cells. This should not be a limiting factor since injection of up
to 3 3 106 cells did not significantly alter the morphology of
treated muscles and producer cell lines can easily be grown in
large quantities. The transplantation procedure also proved
feasible in immunocompetent mdx mice under short-term im-
munosuppression with the drug FK506. Thus, an appropriate
temporary immunosuppressive regimen and a well-designed
protocol for mitotic-inactivation of producer cells may result in
the ability to control the time and progression of gene transfer
Figure 5. Identification of 
probable satellite cells 
transduced in vivo with 
DyBIN vector. Muscle sec-
tions of nude/mdx mice 
transplanted with Am-
pliDyBIN producer cells 
were doubly immunola-
beled with antidystrophin 
antibody (A) or anti–
N-CAM antibody (B); 
3400. Arrows indicate sat-
ellite cells. Some of the 
muscles treated 3 mo ear-
lier were also dissociated, 
primary cultures selected 
in G418 for 12 d, and sub-
jected to Western blot for 
dystrophin detection (C, 
lane 1). Primary cultures 
from untreated mdx mice 
(C, lane 2) and AmpliDy-
BIN 1 producer cells (C, 
lane 3) were also analyzed 
by Western blot. Dy, 229-
kD minidystrophin.
Figure 6. Double immunolabeling for dystrophin and N-CAM. TA 
muscles of Nude/mdx mice received 2.5 3 105 AmpliDyBIN producer 
cells. Double immunolabeling was performed on muscle sections of 
mice killed after 6 wk (A, dystrophin; B, N-CAM) and 24 wk (C, dys-
trophin; D, N-CAM); 3400.
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in vivo. Immunocompetent mice were all killed 3 wk after gene
transfer and no later time points were analyzed, since a cDNA
encoding for the human dystrophin was used which might have
induced an immunoresponse in mice in the long-term.
An important limiting factor for retroviral-mediated gene
therapy is the extent of satellite cell proliferation in vivo while
gene transfer is ongoing and artificial degeneration of skeletal
muscle does not appear a feasible option in DMD patients. Fur-
thermore, it should be noted that the heart which is affected in
DMD patients is refractory to gene transfer by currently avail-
able retroviral vectors. Myocardium does not possess satellite
cells and myocardiocytes lose their ability to divide early in de-
velopment (42). The design of new types of retroviral vectors
(43) may allow in vivo gene transfer in nondividing cells in the
future and, perhaps, clinical application of gene transfer via
transplantation of producer cells, although safety issues will
need careful consideration.
A time course analysis of dystrophin and N-CAM expres-
sion in transplanted nude/mdx mice showed that treated mus-
cles underwent active myofiber remodeling. Evidence was ob-
tained, both in this study and in previous experiments using
the reporter gene Lac-Z (7), that a proportion of satellite cells
could be infected in vivo by the retroviral vector and survive as
muscle precursor cells. We hypothesize that the observed mus-
cle remodeling was a consequence of the degeneration of dys2
fibers and subsequent activation, proliferation, and fusion of
dys1 muscle stem cells transduced in vivo. Indeed, double im-
munolabeling showed the presence of many dys1 and N-CAM1
fibers, especially in the younger mice. Such fibers were likely
to derive from new spontaneous regeneration, since they were
found 6, 12, and 24 wk after BaCl2 injection and N-CAM is
rapidly downregulated after regeneration is completed (40).
Taken together, the data presented here suggest the presence
in transduced mdx mouse muscle of a process similar to ge-
netic normalization which occurs in DMD carriers and leads to
the formation of large clusters of dys1 fibers with time (17).
They also suggest the existence of some type of threshold ef-
fect. Extensive remodeling may not take place if the number of
satellite cells initially infected is too low. The existence of a
threshold effect leading to the repopulation of an organ by ret-
rovirally transduced cells has already been shown in the liver
(44) and may be a more general phenomenon of retroviral-
mediated gene therapy. Further investigations in the mdx and
xcmd animal models are needed to evaluate to what extent
such a phenomenon is active in skeletal muscle. An increase of
clustered dys1 fibers was found in all older animals. However,
the total number of dys1 fibers was not significantly different
at different time points, suggesting also that a proportion of
dys1 fibers was being lost.
The expression of the Becker-type minidystrophin resulted
also in reexpression of a-sarcoglycan. This suggested that, in
many cases, dystrophin reexpression is probably able by itself
to stabilize the DAG complex in adult dystrophic muscle, in
which alterations in the extracellular matrix are presumably
present. This observation is consistent with a previous study in
transgenic mdx mice expressing dystrophin with a chimeric
phenotype in skeletal muscle (45). Furthermore, the percent-
age of N-CAM1 fibers in the dys1 fiber population decreased
in treated older animals, whereas the total number of N-CAM1
fibers did not. This suggested that minidystrophin expression
was exerting a protective effect. However, most dys1 fibers re-
mained centrally nucleated even in the long-term and not all
dys1 fibers were expressing a-sarcoglycan at the sarcolemma.
At present it is not clear whether this is due to the artificially
induced muscle degeneration or to some inability of adult dys-
trophic muscle to recover completely, despite the expression
of dystrophin.
The data presented here may have general consequences
for gene therapy of DMD. It is plausible that focal infection of
satellite cells in a few muscle sites by retroviral vectors could
result in their selective recruitment and more widespread dys-
trophin expression in myofibers. The extent of such selective
myofiber repopulation may depend on the efficiency of satel-
lite cells transduction, their proliferation potential in vivo, and
anatomical barriers. On the other hand, it appears that not all
transduced dys1 fibers are necessarily stabilized and that a
proportion of these fibers may be lost with time. The extent of
dys1 fiber loss may depend on the initial efficiency of in vivo
dystrophin gene transfer, the overall level of correction of the
dystrophic phenotype, and consequent stabilization of individ-
ual muscles.
Acknowledgments
We thank Dr. Y. Takahara for providing AmpliGPE cells, Dr. S. Goff
for providing GP1Am12 cells, Dr. L. Anderson and Dr. G. Morris
for providing antibodies, and Mrs. K. Wells for advice and helpful dis-
cussion.
This work was supported by the Muscular Dystrophy Group of
Great Britain and Northern Ireland, the Leopold Muller Trust, and
the Medical Research Council.
Figure 7. Histograms representing the percentage of N-CAM1 fibers 
in the dys2 fiber population at different time points (black bars) or 
the percentage of N-CAM1 fibers in the dys1 fiber population at dif-
ferent time points (gray bars). Nude/mdx mice were transplanted 
with AmpliDyBIN 1 producer cells and muscle sections were doubly 
immunolabeled for dystrophin and N-CAM. Positive fibers were 
counted in randomly chosen sections. Data are shown as mean6SD. 
The number of N-CAM1 fibers in the dys1 fiber population at the
6 wk time point is significantly different compared to 12 and 24 wk 
time points (Student’s t test: 6 wk versus 12 wk, P , 0.0001; 6 wk versus 
24 wk, P , 0.0001).
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